J
Jan Borén
Researcher at University of Gothenburg
Publications - 422
Citations - 34585
Jan Borén is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Apolipoprotein B & Lipoprotein. The author has an hindex of 78, co-authored 391 publications receiving 27918 citations. Previous affiliations of Jan Borén include Sahlgrenska University Hospital & Temple University.
Papers
More filters
Journal ArticleDOI
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society
Børge G. Nordestgaard,M. John Chapman,Steve E. Humphries,Henry N. Ginsberg,Luis Masana,Olivier S. Descamps,Olov Wiklund,Robert A. Hegele,Frederick J. Raal,Joep C. Defesche,Albert Wiegman,Raul D. Santos,Gerald F. Watts,Klaus G. Parhofer,G. Kees Hovingh,Petri T. Kovanen,Catherine Boileau,Maurizio Averna,Jan Borén,Eric Bruckert,Alberico L. Catapano,Jan Albert Kuivenhoven,Jan Albert Kuivenhoven,P. Pajukanta,Kausik K. Ray,Anton F. H. Stalenhoef,Erik S.G. Stroes,Marja-Riitta Taskinen,Anne Tybjærg-Hansen +28 more
TL;DR: There is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition, familial hypercholesterolaemia.
Journal ArticleDOI
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference,Henry N. Ginsberg,Ian D. Graham,Kausik K. Ray,Chris J. Packard,Eric Bruckert,Robert A. Hegele,Ronald M. Krauss,Frederick J. Raal,Heribert Schunkert,Gerald F. Watts,Jan Borén,Sergio Fazio,Jay D. Horton,Luis Masana,Stephen J. Nicholls,Børge G. Nordestgaard,Børge G. Nordestgaard,Bart van de Sluis,Marja-Riitta Taskinen,Lale Tokgozoglu,Ulf Landmesser,Ulf Landmesser,Ulf Landmesser,Ulrich Laufs,Olov Wiklund,Olov Wiklund,Jane K Stock,M. John Chapman,Alberico L. Catapano +29 more
TL;DR: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
Journal ArticleDOI
Lipoprotein(a) as a cardiovascular risk factor: current status
Børge G. Nordestgaard,M. John Chapman,Kausik K. Ray,Jan Borén,Felicita Andreotti,Gerald F. Watts,Henry N. Ginsberg,Pierre Amarenco,Alberico L. Catapano,Olivier S. Descamps,Edward A. Fisher,Petri T. Kovanen,Jan Albert Kuivenhoven,Philippe Lesnik,Luis Masana,Zeljko Reiner,Marja-Riitta Taskinen,Lale Tokgozoglu,Anne Tybjærg-Hansen +18 more
TL;DR: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated LP(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD.
Journal ArticleDOI
Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications
TL;DR: The finding that certain human populations of individuals who maintain lifelong low plasma levels of apolipoprotein B lipoproteins have an ≈90% decreased risk of coronary artery disease gives hope that further understanding of the pathogenesis of this leading killer could lead to its eradication.
Journal ArticleDOI
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman,Henry N. Ginsberg,Pierre Amarenco,Felicita Andreotti,Jan Borén,Alberico L. Catapano,Olivier S. Descamps,Edward A. Fisher,Petri T. Kovanen,Jan Albert Kuivenhoven,Philippe Lesnik,Luis Masana,Børge G. Nordestgaard,Kausik K. Ray,Zeljko Reiner,Marja-Riitta Taskinen,Lale Tokgozoglu,Anne Tybjærg-Hansen,Gerald F. Watts +18 more
TL;DR: Recommendations will facilitate reduction in the substantial cardiovascular risk that persists in patients with cardiometabolic abnormalities at LDL-C goal, and that therapeutic targeting of elevated triglycerides, a marker of TRL and their remnants, and/or low HDL-C may provide further benefit.